Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests.
Cell Rep Med
; 2(6): 100311, 2021 06 15.
Article
in English
| MEDLINE | ID: covidwho-1230816
ABSTRACT
The ongoing coronavirus disease 2019 (COVID-19) pandemic is a major global public health concern. Although rapid point-of-care testing for detecting viral antigen is important for management of the outbreak, the current antigen tests are less sensitive than nucleic acid testing. In our current study, we produce monoclonal antibodies (mAbs) that exclusively react with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and exhibit no cross-reactivity with other human coronaviruses, including SARS-CoV. Molecular modeling suggests that the mAbs bind to epitopes present on the exterior surface of the nucleocapsid, making them suitable for detecting SARS-CoV-2 in clinical samples. We further select the optimal pair of anti-SARS-CoV-2 nucleocapsid protein (NP) mAbs using ELISA and then use this mAb pair to develop immunochromatographic assay augmented with silver amplification technology. Our mAbs recognize the variants of concern (501Y.V1-V3) that are currently in circulation. Because of their high performance, the mAbs of this study can serve as good candidates for developing antigen detection kits for COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunoassay
/
Coronavirus Nucleocapsid Proteins
/
SARS-CoV-2
/
Antibodies, Monoclonal
/
Epitopes
Type of study:
Diagnostic study
/
Prognostic study
/
Randomized controlled trials
Topics:
Variants
Limits:
Animals
/
Humans
Language:
English
Journal:
Cell Rep Med
Year:
2021
Document Type:
Article
Affiliation country:
J.xcrm.2021.100311
Similar
MEDLINE
...
LILACS
LIS